Trial · NCT04837885
Intra-arterial Hepatic (IAH) Infusion of Radiolabelled Somatostatin Analogs in GEP-NET Patients With Dominant Liver Metastases
NCT04837885, Phase 2, Recruiting, University Hospital, Bordeaux
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Intra-arterial Hepatic (IAH) Infusion of Radiolabelled Somatostatin Analogs in GEP-NET Patients With Dominant Liver Metastases. Trials, record NCT04837885. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04837885
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Intra-arterial Hepatic (IAH) Infusion of Radiolabelled Somatostatin Analogs in GEP-NET Patients With Dominant Liver Metastases
- NCT number
- NCT04837885
- Status
- Recruiting
- Phases
- Phase 2
- Enrollment
- 23 participants, estimated
- Lead sponsor
- University Hospital, Bordeaux
- Conditions
- Neuroendocrine Tumor, Liver Metastases, Neuroendocrine Gastroenteropancreatic Tumour
- Interventions
Positron emission tomography computed tomography (PET/CT) with Intra-hepatic (IAH) injection, Positron emission tomography computed tomography (PET/CT) with Intravenous (IV) injection, LUTATHERA® by intra-arterial hepatic (IAH) injection, Scan
- First posted
- 2021-04-08
- Last updated
- 2025-07-23
Source ClinicalTrials.gov
Registered outcomes13
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Standardized uptake value (SUVmax) on liver metastases | Day 0 (First PET/CT) | Standardized uptake value (SUVmax) on liver metastase obtained on PET/CT imaging after injection of 68Ga-DOTA-peptides |
| Primary | Standardized uptake value (SUVmax) on liver metastases | Day 3 (second PET/CT) | Standardized uptake value (SUVmax) on liver metastase obtained on PET/CT imaging after injection of 68Ga-DOTA-peptides |
| Secondary | Standardized uptake value (SUVmax) on healthy liver | Day 0 (First PET/CT) | Standardized uptake value (SUVmax) on healthy liver obtained on PET/CT imaging after injection of 68Ga-DOTA-peptides |
| Secondary | Standardized uptake value (SUVmax) on healthy liver | Day 3 (second PET/CT) | Standardized uptake value (SUVmax) on healthy liver obtained on PET/CT imaging after injection of 68Ga-DOTA-peptides |
| Secondary | Standardized uptake value (SUVmax) on kidneys | Day 0 (First PET/CT) | Standardized uptake value (SUVmax) on kidneys obtained on PET/CT imaging after injection of 68Ga-DOTA-peptides |
| Secondary | Standardized uptake value (SUVmax) on kidneys | Day 3 (second PET/CT) | Standardized uptake value (SUVmax) on kidneys obtained on PET/CT imaging after injection of 68Ga-DOTA-peptides |
| Secondary | Standardized uptake value (SUVmax) on bone marrow | Day 0 (First PET/CT) | Standardized uptake value (SUVmax) on bone marrow obtained on PET/CT imaging after injection of 68Ga-DOTA-peptides |
| Secondary | Standardized uptake value (SUVmax) on bone marrow | Day 3 (second PET/CT) | Standardized uptake value (SUVmax) on bone marrow obtained on PET/CT imaging after injection of 68Ga-DOTA-peptides |
| Secondary | Standardized uptake value (SUVmax) on spleen | Day 0 (First PET/CT) | Standardized uptake value (SUVmax) on spleen obtained on PET/CT imaging after injection of 68Ga-DOTA-peptides |
| Secondary | Standardized uptake value (SUVmax) on spleen | Day 3 (second PET/CT) | Standardized uptake value (SUVmax) on spleen obtained on PET/CT imaging after injection of 68Ga-DOTA-peptides |
1 to 10 of 13Source ClinicalTrials.gov
See all 13 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04837885
GET https://conductscience.org/api/trials/v1/NCT04837885/registered